Peeples M E, Collins P L
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0720, USA.
J Virol. 2000 Jan;74(1):146-55. doi: 10.1128/jvi.74.1.146-155.2000.
The 3' termini of the genomic and antigenomic RNAs of human respiratory syncytial virus (RSV) are identical at 10 of the first 11 nucleotide positions and 21 of the first 26 positions. These conserved 3'-terminal sequences are thought to contain the genomic and antigenomic promoters. Furthermore, the complement of each conserved sequence (i.e., the 5' end of the RNA it encodes) might contain an encapsidation signal. Using an RSV minigenome system, we individually mutated each of the last seven nucleotides in the 5' trailer region of the genome. We analyzed effects of these mutations on encapsidation of the T7 polymerase-transcribed negative-sense genome, its ability to function as a template for RSV-driven synthesis of positive-sense antigenome and mRNA, and the ability of this antigenome to be encapsidated and to function as template for the synthesis of more genome. As a technical complication, mutations in the last five nucleotides of the trailer region were found to affect the efficiency of the adjoining T7 promoter over more than a 10-fold range, even though three nonviral G residues had been included between the core promoter and the trailer to maximize the efficiency of promoter activity. This was controlled in all experiments by monitoring the levels of total and encapsidated genome. The efficiency of encapsidation of the T7 polymerase-transcribed genome was not affected by any of the trailer mutations. Furthermore, neither the efficiency of positive-sense RNA synthesis from the genome nor the efficiency of encapsidation of the encoded antigenome was affected by the mutations. However, nucleotide substitution at positions 2, 3, 6, or 7 relative to the 5' end of the trailer blocked the production of progeny genome, whereas substitution at positions 1 and 5 allowed a low level of genome production and substitutions at position 4 were tolerated. Position 4 is the only one of the seven positions examined that is not conserved between the 3' ends of genomic and antigenomic RNA. The mutations that blocked the synthesis of progeny genome thus limited RNA replication to one step, namely, the synthesis and encapsidation of antigenome. Restoration of terminal complementarity for one of the trailer mutants by making a compensatory mutation in the leader region did not restore synthesis of genomic RNA, confirming that its loss was not due to reduced terminal complementarity. Interestingly, this leader mutation appeared to prevent antigenome synthesis with only a slight effect on mRNA synthesis, apparently providing a dissociation between these two synthetic activities. Genomes in which the terminal 24 or 325 nucleotides of the trailer have been deleted were competent for encapsidation and the synthesis of mRNA and antigenomic RNA, further confirming that terminal complementarity was not required for these functions.
人类呼吸道合胞病毒(RSV)基因组RNA和反基因组RNA的3'末端在前11个核苷酸位置中的10个以及前26个位置中的21个是相同的。这些保守的3'末端序列被认为包含基因组和反基因组启动子。此外,每个保守序列的互补序列(即它所编码RNA的5'末端)可能包含一个包装信号。利用RSV微型基因组系统,我们分别对基因组5'拖尾区域的最后七个核苷酸进行了突变。我们分析了这些突变对T7聚合酶转录的负义基因组包装的影响,其作为RSV驱动的正义反基因组和mRNA合成模板的功能,以及该反基因组被包装并作为更多基因组合成模板的能力。作为一个技术难题,尽管在核心启动子和拖尾之间包含了三个非病毒G残基以最大化启动子活性效率,但发现拖尾区域最后五个核苷酸的突变会在超过10倍的范围内影响相邻T7启动子的效率。在所有实验中,通过监测总基因组和包装基因组的水平来控制这一情况。T7聚合酶转录的基因组的包装效率不受任何拖尾突变的影响。此外,基因组正义RNA合成的效率以及编码的反基因组的包装效率都不受这些突变的影响。然而,相对于拖尾5'末端的第2、3、6或7位核苷酸的替换阻断了子代基因组的产生,而第1和5位的替换允许低水平的基因组产生,第4位的替换则可被耐受。第4位是所检测的七个位置中唯一一个在基因组RNA和反基因组RNA的3'末端之间不保守的位置。因此,阻断子代基因组合成的突变将RNA复制限制在一个步骤,即反基因组的合成和包装。通过在前导区域进行补偿性突变来恢复其中一个拖尾突变体的末端互补性,并没有恢复基因组RNA的合成,这证实其缺失不是由于末端互补性降低所致。有趣的是,这种前导突变似乎仅对mRNA合成有轻微影响就阻止了反基因组的合成,显然在这两种合成活动之间产生了分离。拖尾末端24或325个核苷酸被删除的基因组能够进行包装以及mRNA和反基因组RNA的合成,进一步证实这些功能不需要末端互补性。